The Latest Breaking News from Regenxbio

RGX-202 Duchenne Gene Therapy Met Its Phase 3 Goal as New Data Detail Two Resolved Serious Side Effects

RGX-202 met its Phase 3 Duchenne goal, and new data detail two resolved serious side effects. What families should know before a possible FDA decision.

Medical Daily · Oct 20

Hunter Syndrome Gene Therapy Halted by FDA After Spine Scans Show Small Masses in Five Children

FDA placed REGENXBIO's RGX-121 on clinical hold after spine MRIs showed nodules or cysts in five Hunter syndrome trial participants.

Medical Daily · Aug 25

Regenxbio Unveils 12-Month Data For Gene Therapy Soon After FDA Delays Review Date

On Friday, REGENXBIO Inc. (NASDAQ:RGNX) shared new data from the Phase 1/2/3 CAMPSIITE trial of clemidsogene lanparvovec (RGX-121) for the treatment of patients with Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome, at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025.

Benzinga · Sep 5, 2025

Regenxbio's Return On Capital Employed Overview

Regenxbio (NASDAQ:RGNX) brought in sales totaling $22.22 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 126.09%, resulting in a loss of $76.72 million.

Benzinga · May 24, 2022

Expert Ratings for Regenxbio

Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga · May 24, 2022

5 Value Stocks In The Healthcare Sector

What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

Benzinga · May 16, 2022

Expert Ratings for Regenxbio

Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings within the last quarter:

Benzinga · May 5, 2022

Regenxbio's Return On Capital Employed Overview

According to Benzinga Pro, during Q4, Regenxbio (NASDAQ:RGNX) earned $294.02 million, a 603.42% increase from the preceding quarter. Regenxbio also posted a total of $398.65 million in sales, a 1195.47% increase since Q3.

Benzinga · Mar 7, 2022

Expert Ratings For Regenxbio

Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga · Mar 2, 2022

Regenxbio: Q4 Earnings Insights

Regenxbio (NASDAQ:RGNX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Regenxbio beat estimated earnings by 41.61%, reporting an EPS of $6.67 versus an estimate of $4.71.

Benzinga · Mar 1, 2022